The Catalan biopharmaceutical Ona Therapeutics has closed a Series B funding round of 74.2 million euros to continue developing its cancer treatments. The new capital injection has been co-led by Valencian investor Columbus Venture Partners and French manager Mérieux Equity Partners, in addition to the public Cofides and the family office Korys. Current partners also participated: Asabys Partners, Alta Life Sciences, Bpifrance, CDTI, FundPlus NV, and Ysios Capital.